> top > docs > PMC:7594251 > spans > 41128-41958 > annotations

PMC:7594251 / 41128-41958 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T39453 530-541 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T27 353-359 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T28 441-460 Disease denotes metastatic melanoma http://purl.obolibrary.org/obo/MONDO_0005191
T29 452-460 Disease denotes melanoma http://purl.obolibrary.org/obo/MONDO_0005105
T30 522-550 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T31 530-550 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T32 542-550 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T296 480-481 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T297 552-555 http://purl.obolibrary.org/obo/CLO_0001196 denotes 225
T298 652-653 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T408 118-123 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T409 223-227 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T410 261-272 Chemical denotes vemurafenib http://purl.obolibrary.org/obo/CHEBI_63637
T411 310-314 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T412 489-493 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T413 583-587 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T414 659-668 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T415 755-766 Chemical denotes vemurafenib http://purl.obolibrary.org/obo/CHEBI_63637
T416 768-778 Chemical denotes venetoclax http://purl.obolibrary.org/obo/CHEBI_133021
T417 802-807 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
542 341-345 Gene denotes BRAF Gene:673
543 654-658 Gene denotes CDK4 Gene:1019
544 427-435 Species denotes patients Tax:9606
545 508-516 Species denotes patients Tax:9606
546 261-272 Chemical denotes vemurafenib MESH:D000077484
547 280-291 Chemical denotes Vemurafenib MESH:D000077484
548 468-478 Chemical denotes Venetoclax MESH:C579720
549 615-619 Chemical denotes FBDD
550 755-766 Chemical denotes vemurafenib MESH:D000077484
551 353-359 Disease denotes cancer MESH:D009369
552 452-460 Disease denotes melanoma MESH:D008545
553 522-550 Disease denotes chronic lymphocytic leukemia MESH:D015451

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T8 353-359 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T9 452-460 Phenotype denotes melanoma http://purl.obolibrary.org/obo/HP_0002861
T10 522-550 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T286 0-203 Sentence denotes At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222].
T287 204-279 Sentence denotes The first marketed drug derived via the FBDD approach is vemurafenib [223].
T288 280-467 Sentence denotes Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224].
T289 468-686 Sentence denotes Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221].
T290 687-830 Sentence denotes The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2.